The efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of an open-labeled multicenter study

Terapevticheskii Arkhiv

Volumn 82, Issue 10, 2010, Pages 41-46

  Bunchuk, N V ^a   Rumyantseva, O A ^a   Loginova, E Yu ^a   Bochkova, A G ^a   Storozhakov, G I ^b   Ettinger, O A ^b   Kosyura, S D ^b   Kamalovo, R G ^c   Valishina, L M ^c  

^a V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^b PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^c Republican Rheumatology Center of Bashkortostan   (Russian Federation)

Author keywords

Ankylosing spondylitis; Infliximab; Treatment

Indexed keywords

ANTIINFLAMMATORY AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650061859     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Braun J., Brandt J., Listing J. et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-1193.
2. Van der Heijde D., Dijkmans B., Geusens P. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized, placebo-controlled trial (ASSERT). Arthr. and Rheum. 2005; 52: 582-591.
3. Maksymowych W., Jhangrl G., Lambert R. et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J. Rheumatol. 2002; 29: 259-265.
4. Nikas S., Alamanos Y., Voulgari P. et al. Infliximab therapy in ankylosing spondylitis: an observational study. Ann. Rheum. Dis. 2005; 64: 940-942.
5. Braun J., Baraliakos X., Listing J. et al. Persistent clinical efficacy and safety of anti-TNF-a therapy with infliximab in patients with ankylosing spondylitis over 5 years - evidence for different types of response. Ann. Rheum. Dis. 2008; 67: 340-345.
6. Van der Linden S., Valkenburg H., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthr. and Rheuni. 1984; 27: 361-368.
7. Anderson J.J. Baron G. Van Der Heijde D. Felson D.T. Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis Arthritis and Rheumatism 2001 44 8 1876-1886 DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F 10. Anderson J., Baron G., van der Heijde D. et al. Ankylosing Spondylitis Assessment Group preliminary definition of shortterm improvement in ankylosing spondylitis. Arthr. and Rheum. 2001: 44: 1876-1886. (Pubitemid 32758236)
8. Braun J., Brandt J., Listing J. et al. Longterm efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthr. and Rheum. 2003; 48: 2224-2233.
9. Breban M., Ravaud P., Claudepierre P. et al. Maintenance of infliximab treatment in ankylosing spondylitis results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthr. and Rheum. 2008; 58: 88-97.
10. de Vries M., Wolbink G., Stapel S. et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann. Rheum. Dis. 2007; 66: 1252-1254.
11. van den Bosch F., Devinck M., Kruithof E. et al. 5-year safety and efficacy follow-up in 107 spondyloarthropathy patients with continued long-term infliximab treatment. Ann. Rheum. Dis. 2005; 64 (Suppl. 3): 1079.
12. Remicade (infliximabe) current (May 2007) prescribing information. http://www.fda.gov
13. Dixon W., Lunt W., Hyrich K. et al. Rates of serious infection, including sitespecific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthr. and Rheum. 2006; 54: 2368-2376.
14. Beglinger C. Dudler J. Mottet C. Nicod L. Seibold F. Villiger P.M. Zellweger J.-P. Screening for tuberculosis infection before initiation of anti-TNF-α therapy Swiss Medical Weekly 2007 137 43 44 621-622 17. Beglinger C., Dudler J., Mottet C. et al. Screening for tuberculosis infection before initiation of anti-TNF-α-therapy. Swiss Med. Wkly 2007; 137: 621-622. (Pubitemid 350114753)
15. Collamer A., Guerrero K., Henning J., Battafarano D. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action. Arthr. and Rheum. 2008; 59: 996-1001.
16. Landewe R., Rump B., van der Heijde D., van der Linden S. Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists. Ann. Rheum. Dis. 2004; 63: 530-534.
17. Cruyssen B., Ribbens C., Boonen A. et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann. Rheum. 2007; 66: 1072-1077.
18. Dawes P., Packham J., Mucklow J. TNF therapy for spondyloarthropathy: can we marshal the argument? Rheumatology 2004; 43:1069-1071.